You are not authorized to access this page.
Search Within

Paul Chapman

Formats
  1. Journal Article (206)
  2. Meeting Abstract (109)
  3. Book Section (8)
  4. Conference Paper (1)
  5. Editorial (1)
  6. Research Letter (1)
  7. Review (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (327)
  2. Department of Medicine (327)
  3. Melanoma and Immunotherapeutics Service (327)
  4. Solid Tumor Oncology Division (327)
  5. GSK Faculty (133)
  6. Melanoma Disease Management Team (93)

More Groups

People
  1. Jedd Wolchok (107)
  2. Katherine Panageas (77)
  3. Alan Houghton (60)
  4. Michael Postow (55)
  5. Margaret Callahan (50)
  6. Alexander Shoushtari (46)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (8)
  4. 2022 (2)
  5. 2021 (9)
  6. 2020 (8)

More Years

Publications
  1. Journal of Clinical Oncology (88)
  2. Clinical Cancer Research (29)
  3. Cancer Research (15)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (13)
  5. New England Journal of Medicine (11)
  6. Melanoma Research (10)

More Publications

Publishers
  1. American Society of Clinical Oncology (94)
  2. American Association for Cancer Research (60)
  3. Elsevier Inc. (22)
  4. Lippincott Williams & Wilkins (19)
  5. Wiley Blackwell (19)
  6. Oxford University Press (13)

More Publishers

Results (327)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety of infusing ipilimumab over 30 minutes
    Journal Article

    Momtaz, P.; Park, V.; Panageas, K. S.; Postow, M. A.; Callahan, M.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center
    Journal Article

    Horvat, T. Z.; Adel, N. G.; Dang, T. O.; Momtaz, P.; Postow, M. A.; Callahan, M. K.; Carvajal, R. D.; Dickson, M. A.; D'Angelo, S. P.; Woo, K. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Pilot trial of selecting molecularly guided therapy for patients with non-V600 BRAF-mutant metastatic melanoma: Experience of the SU2C/MRA melanoma dream team
    Journal Article

    LoRusso, P. M.; Boerner, S. A.; Pilat, M. J.; Forman, K. M.; Zuccaro, C. Y.; Kiefer, J. A.; Liang, W. S.; Hunsberger, S.; Redman, B. G.; Markovic, S. N.; more...
    Molecular Cancer Therapeutics (2015)

    Fulltext@MSK | Save
  • Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition
    Journal Article

    Carvajal, R. D.; Lawrence, D. P.; Weber, J. S.; Gajewski, T. F.; Gonzalez, R.; Lutzky, J.; O'Day, S. J.; Hamid, O.; Wolchok, J. D.; Chapman, P. B.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • Correlating surrogate endpoints with overall survival at the individual patient level in BRAF-mutated metastatic melanoma patients treated with vemurafenib
    Meeting Abstract

    Zabor, E. C.; Heller, G.; Schwartz, L. H.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B)
    Meeting Abstract

    Yee, M. K.; Lin, Y.; Gorantla, V. C.; Butterfield, L. H.; Kluger, H. M.; Chapman, P. B.; Gangadhar, T. C.; Milhem, M. M.; Pavlick, A. C.; Amaravadi, R. K.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events
    Meeting Abstract

    Shoushtari, A. N.; Postow, M. A.; Horvat, T. Z.; Adel, N. G.; Dang, T.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Safety of infusing ipilimumab (ipi) over 30 minutes (min)
    Meeting Abstract

    Momtaz, P.; Park, V.; Panageas, K.; Guillen, J. D.; Postow, M. A.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma
    Meeting Abstract

    Algazi, A. P.; Muthukumar, A. H.; O'Brien, K.; Lencioni, A.; Tsai, K. K.; Kadafour, M.; Chapman, P. B.; Daud, A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases
    Journal Article

    Harding, J. J.; Catalanotti, F.; Munhoz, R. R.; Cheng, D. T.; Yaqubie, A.; Kelly, N.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Lacouture, M. E.; more...
    The Oncologist (2015)

    Fulltext@MSK | Save